WuXi XDC, a global CDMO company, and South Korea-based LegoChem Biosciences (141080KS) announced on Wednesday that they have signed a Memorandum of Understanding to establish a strategic collaboration in development and manufacturing of antibody-drug conjugates (ADCs).

The collaboration will allow LegoChem Biosciences to have access to WuXi XDC's integrated services in mAb, linker, payload, analytical and formulation development and antibody-drug conjugates drug substance and drug product development and manufacturing. WuXi XDC is to offer a complete range of development and manufacturing services in one centralised region, which is within two hours' driving distance.

Dr Yong-Zu Kim, CEO and president of LegoChem Biosciences, said, 'We're excited to collaborate with WuXi XDC. This partnership will allow us to leverage WuXi XDC's world-class expertise in both innovative conjugation technologies and the comprehensive capabilities for the antibody-drug conjugates development and manufacturing. We're looking forward to making more antibody-drug conjugates products accessible to the patients.'

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE